Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Securities Litigation Arising from Alzheimer's Drug Treatments
Biogen's Aduhelm, approved by FDA in 2021, faced controversy after post hoc analysis showed mixed results. The drug's launch was unsuccessful, leading to securities litigation. In 2023, an appellate court partially reversed a district court's decision, focusing on a statement about the drug's efficacy. Meanwhile, Cassava Sciences, another company with an Alzheimer's drug, faced similar litigation challenges.
Lilly gets second approval, in Japan, for Alzheimer's drug
Eli Lilly's Alzheimer's drug Kisunla (donanemab) gains approval in Japan, following US FDA approval in July. Kisunla targets early symptomatic Alzheimer's, showing significant cognitive decline reduction in the TRAILBLAZER-ALZ 2 study. Japan's aging population makes it a key market, with dementia cases expected to reach 5 million by 2030, mostly Alzheimer's. Lilly emphasizes Kisunla's cost-effectiveness due to fixed treatment duration.
Biogen and UCB Promising Phase-III Trial Data for Lupus; CAR T-Cell Therapy Another
Biogen and UCB report promising Phase-III trial data for lupus treatment, dapirolizumab pegol, potentially reshaping the market. UC Davis Health explores CAR T-cell therapy as an alternative for lupus and lupus nephritis, aiming for targeted treatment.
Dapirolizumab Pegol Meets Primary Endpoint in Phase 3 Study for SLE
The phase 3 PHOENYCS GO study met its primary endpoint, showing clinical improvement in moderate-to-severe systemic lupus erythematosus (SLE) patients treated with dapirolizumab pegol plus standard-of-care. UCB and Biogen plan to initiate a second phase 3 study in 2024, with further data to be presented at a future medical meeting.
UCB and Biogen lupus drug succeeds in Phase III, but data yet to be released
UCB and Biogen's lupus drug, dapirolizumab pegol, met primary endpoint in Phase III PHOENYCS GO trial, showing improvement in moderate-to-severe SLE. The drug also demonstrated clinical improvements in secondary endpoints and a consistent safety profile. UCB's stock rose 2.57% post-announcement. Detailed data will be presented at an upcoming medical conference.
UCB and Biogen Announce Positive Phase III Clinical Trial Results for Dapirolizumab Pegol
UCB and Biogen announced positive Phase III PHOENYCS GO study results for dapirolizumab pegol, a treatment for moderate-to-severe systemic lupus erythematosus (SLE), showing improvement in disease activity at week 48. The drug, which blocks B cell activation, also reduced disease flares. A second Phase III study, PHOENYCS FLY, will start in 2024.
Biogen and UCB stay the course for phase III lupus success
Biogen and UCB's anti-CD40L candidate, dapirolizumab pegol, met primary endpoint in phase III lupus trial, showing improvement over placebo and standard of care at 48 weeks.
Eli Lilly's Alzheimer's drug approved in Japan
Eli Lilly's Alzheimer's drug, donanemab, approved by Japan's health ministry, offering another treatment option after Eisai and Biogen's Leqembi. Kisunla, sold in the U.S., slows memory and thinking problems by 29% but has risks of brain swelling and bleeding. Unlike Leqembi, Kisunla has finite dosing, allowing patients to stop treatment when amyloid plaques are no longer visible.
© Copyright 2025. All Rights Reserved by MedPath